All News

IDWeek 2023. New study found just slightly more than half of prescriptions for cabotegravir for HIV PrEP resulted in at least 1 injection, suggesting limitations in use and access to the injectable HIV integrase inhibitor.

IDWeek 2023: Older adults hospitalized with respiratory syncytial virus were more likely to be women, be immunocompromised, and to have traveled within the prior 2 weeks,

IDWeek 2023. Results highlight potential impact of influenza vaccination in reducing CV, respiratory, and other complications in adults aged ≥65 years with underlying chronic conditions.

The phase 2 study found that nAB responses against epithelial cell infection were strong after each mRNA-1647 dose and sustained through 12 months.

A phase 3 study found VE from a single shot against RSV-LRTD in adults aged ≥60 years persisted through a second season; revaccination did not increase protection.

IDWeek 2023. The study identified disparities in coverage related to age, race, ethnicity, household income, insurance status, and prior influenza vaccination.

IDWeek 2023. New data shows non-Hispanic Black patients had a 13% lower likelihood of getting the influenza vaccine compared to non-Hispanic White patients.

A modeling study projected an annual reduction of nearly 25 000 infant hospitalizations and 46 000 ED encounters following maternal vaccination against RSV.

Immune response in older adults after receiving both vaccines in the same visit was noninferior to sequential administration and the safety profile was acceptable.

Candace Westgate, DO, MPH, FACOG, and Mylynda Massart, MD, PhD, introduce this series on early cancer detection, multi-cancer detection tests, and the role of primary care physicians (PCPs) in preventative care.

The study found that measles antibody levels during 2 long-term follow-ups fell lower than those observed before receipt of the third MMR dose.

The study findings on enhanced immunity from a third mRNA-1273 dose and specific population benefits will help build effective public health policy, authors say.

The intranasal delivery and live attenuated form of CoviLiv may strengthen immune response and vaccine acceptance and uptake in populations and regions where both are low.

Researchers say findings demonstrate the capacity to use an existing influenza vaccine effectiveness network to study a large immunocompromised population.

The phase 3 semaglutide kidney outcomes trial will be stopped immediately with FLOW read out expected in early 2024, the company said.

IDWeek 2023: In a large cohort of people living with HIV, those switching from oral ART to long acting CAB+RPV were more than 4x as likely to adhere to the regimen.

Approved for persons with HIV with undetectable VL, CAB+RPV LA may also be appropriate for those with VL ≥50 copies when the therapy is initiated, according to new findings.

IDWeek 2023: Adolescents expressed a preference for a combination vaccine covering serogroups A, B, C, W, Y of invasive meningococcal disease, reported researchers.